Cipla subsidiary Invagen signs partnership with Qilu on biosimilar licensing
Invagen Pharmaceuticals, a wholly owned subsidiary of Cipla, announced a strategic partnership with Qilu for the licensing and supply of a biosimilar to Keytruda (pembrolizumab) in the US.